<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20231108031047&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20231108031047&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 08 Nov 2023 08:10:51 +0000</lastbuilddate>
<pubDate>Tue, 07 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Ventricular arrhythmias during ST-segment elevation myocardial infarction and arrhythmic complications during recurrent ischaemic events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37935589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 3:ehad740. doi: 10.1093/eurheartj/ehad740. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37935589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37935589</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad740>10.1093/eurheartj/ehad740</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37935589</guid>
<pubDate>Tue, 07 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Marina M Demidova</dc:creator>
<dc:creator>Fredrik Holmqvist</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Pyotr G Platonov</dc:creator>
<dc:date>2023-11-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ventricular arrhythmias during ST-segment elevation myocardial infarction and arrhythmic complications during recurrent ischaemic events</dc:title>
<dc:identifier>pmid:37935589</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad740</dc:identifier>
</item>
<item>
<title>Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37935588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 3:ehad747. doi: 10.1093/eurheartj/ehad747. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37935588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37935588</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad747>10.1093/eurheartj/ehad747</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37935588</guid>
<pubDate>Tue, 07 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Riccardo M Inciardi</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-11-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure</dc:title>
<dc:identifier>pmid:37935588</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad747</dc:identifier>
</item>
<item>
<title>Mendelian randomization for cardiovascular diseases: principles and applications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37935836/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>Large-scale genome-wide association studies conducted over the last decade have uncovered numerous genetic variants associated with cardiometabolic traits and risk factors. These discoveries have enabled the Mendelian randomization (MR) design, which uses genetic variation as a natural experiment to improve causal inferences from observational data. By analogy with the random assignment of treatment in randomized controlled trials, the random segregation of genetic alleles when DNA is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 3:ehad736. doi: 10.1093/eurheartj/ehad736. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Large-scale genome-wide association studies conducted over the last decade have uncovered numerous genetic variants associated with cardiometabolic traits and risk factors. These discoveries have enabled the Mendelian randomization (MR) design, which uses genetic variation as a natural experiment to improve causal inferences from observational data. By analogy with the random assignment of treatment in randomized controlled trials, the random segregation of genetic alleles when DNA is transmitted from parents to offspring at gamete formation is expected to reduce confounding in genetic associations. Mendelian randomization analyses make a set of assumptions that must hold for valid results. Provided that the assumptions are well justified for the genetic variants that are employed as instrumental variables, MR studies can inform on whether a putative risk factor likely has a causal effect on the disease or not. Mendelian randomization has been increasingly applied over recent years to predict the efficacy and safety of existing and novel drugs targeting cardiovascular risk factors and to explore the repurposing potential of available drugs. This review article describes the principles of the MR design and some applications in cardiovascular epidemiology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37935836/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37935836</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad736>10.1093/eurheartj/ehad736</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37935836</guid>
<pubDate>Tue, 07 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Susanna C Larsson</dc:creator>
<dc:creator>Adam S Butterworth</dc:creator>
<dc:creator>Stephen Burgess</dc:creator>
<dc:date>2023-11-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mendelian randomization for cardiovascular diseases: principles and applications</dc:title>
<dc:identifier>pmid:37935836</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad736</dc:identifier>
</item>
<item>
<title>Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37935833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Discontinuing RAS inhibitors before non-cardiac surgery did not reduce myocardial injury, and could increase the risk of clinically significant acute hypertension. These findings require confirmation in future studies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 7:ehad716. doi: 10.1093/eurheartj/ehad716. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Haemodynamic instability is associated with peri-operative myocardial injury, particularly in patients receiving renin-angiotensin system (RAS) inhibitors (angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers). Whether stopping RAS inhibitors to minimise hypotension, or continuing RAS inhibitors to avoid hypertension, reduces peri-operative myocardial injury remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From 31 July 2017 to 1 October 2021, patients aged ≥60 years undergoing elective non-cardiac surgery were randomly assigned to either discontinue or continue RAS inhibitors prescribed for existing medical conditions in six UK centres. Renin-angiotensin system inhibitors were withheld for different durations (2-3 days) before surgery, according to their pharmacokinetic profile. The primary outcome, masked to investigators, clinicians, and patients, was myocardial injury [plasma high-sensitivity troponin-T (hs-TnT) ≥ 15 ng/L within 48 h after surgery, or ≥5 ng/L increase when pre-operative hs-TnT ≥15 ng/L]. Pre-specified adverse haemodynamic events occurring within 48 h of surgery included acute hypertension (>;180 mmHg) and hypotension requiring vasoactive therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Two hundred and sixty-two participants were randomized to continue (n = 132) or stop (n = 130) RAS inhibitors. Myocardial injury occurred in 58 (48.3%) patients randomized to discontinue, compared with 50 (41.3%) patients who continued, RAS inhibitors [odds ratio (for continuing): 0.77; 95% confidence interval (CI) 0.45-1.31]. Hypertensive adverse events were more frequent when RAS inhibitors were stopped [16 (12.4%)], compared with 7 (5.3%) who continued RAS inhibitors [odds ratio (for continuing): 0.4; 95% CI 0.16-1.00]. Hypotension rates were similar when RAS inhibitors were stopped [12 (9.3%)] or continued [11 (8.4%)].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Discontinuing RAS inhibitors before non-cardiac surgery did not reduce myocardial injury, and could increase the risk of clinically significant acute hypertension. These findings require confirmation in future studies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37935833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37935833</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad716>10.1093/eurheartj/ehad716</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37935833</guid>
<pubDate>Tue, 07 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gareth L Ackland</dc:creator>
<dc:creator>Akshaykumar Patel</dc:creator>
<dc:creator>Tom E F Abbott</dc:creator>
<dc:creator>Salma Begum</dc:creator>
<dc:creator>Priyanthi Dias</dc:creator>
<dc:creator>David R Crane</dc:creator>
<dc:creator>Sameer Somanath</dc:creator>
<dc:creator>Alexander Middleditch</dc:creator>
<dc:creator>Stuart Cleland</dc:creator>
<dc:creator>Ana Gutierrez Del Arroyo</dc:creator>
<dc:creator>David Brealey</dc:creator>
<dc:creator>Rupert M Pearse</dc:creator>
<dc:creator>Stopping Perioperative ACE-inhibitors or angiotensin-II receptor blockers (SPACE) trial investigators</dc:creator>
<dc:date>2023-11-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial</dc:title>
<dc:identifier>pmid:37935833</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad716</dc:identifier>
</item>
<item>
<title>Endpoint adjudication in cardiovascular clinical trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37935635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>Endpoint adjudication (EA) is a common feature of contemporary randomized controlled trials (RCTs) in cardiovascular medicine. Endpoint adjudication refers to a process wherein a group of expert reviewers, known as the clinical endpoint committee (CEC), verify potential endpoints identified by site investigators. Events that are determined by the CEC to meet pre-specified trial definitions are then utilized for analysis. The rationale behind the use of EA is that it may lessen the potential...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 3:ehad718. doi: 10.1093/eurheartj/ehad718. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Endpoint adjudication (EA) is a common feature of contemporary randomized controlled trials (RCTs) in cardiovascular medicine. Endpoint adjudication refers to a process wherein a group of expert reviewers, known as the clinical endpoint committee (CEC), verify potential endpoints identified by site investigators. Events that are determined by the CEC to meet pre-specified trial definitions are then utilized for analysis. The rationale behind the use of EA is that it may lessen the potential misclassification of clinical events, thereby reducing statistical noise and bias. However, it has been questioned whether this is universally true, especially given that EA significantly increases the time, effort, and resources required to conduct a trial. Herein, we compare the summary estimates obtained using adjudicated vs. non-adjudicated site designated endpoints in major cardiovascular RCTs in which both were reported. Based on these data, we lay out a framework to determine which trials may warrant EA and where it may be redundant. The value of EA is likely greater when cardiovascular trials have nuanced primary endpoints, endpoint definitions that align poorly with practice, sub-optimal data completeness, greater operator variability, and lack of blinding. EA may not be needed if the primary endpoint is all-cause death or all-cause hospitalization. In contrast, EA is likely merited for more nuanced endpoints such as myocardial infarction, bleeding, worsening heart failure as an outpatient, unstable angina, or transient ischaemic attack. A risk-based approach to adjudication can potentially allow compromise between costs and accuracy. This would involve adjudication of a small proportion of events, with further adjudication done if inconsistencies are detected.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37935635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37935635</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad718>10.1093/eurheartj/ehad718</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37935635</guid>
<pubDate>Tue, 07 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Muhammad Shariq Usman</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Omar Baqal</dc:creator>
<dc:creator>Gary Michael Felker</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2023-11-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Endpoint adjudication in cardiovascular clinical trials</dc:title>
<dc:identifier>pmid:37935635</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad718</dc:identifier>
</item>
<item>
<title>Routine stress testing in diabetic patients after percutaneous coronary intervention: the POST-PCI trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37933514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Despite being at higher risk for adverse clinical events, patients with diabetes who had undergone high-risk PCI did not derive incremental benefit from routine surveillance stress testing compared with standard care alone during follow-up.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 2:ehad722. doi: 10.1093/eurheartj/ehad722. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The optimal follow-up surveillance strategy for high-risk diabetic patients with had undergone percutaneous coronary intervention (PCI) remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The POST-PCI (Pragmatic Trial Comparing Symptom-Oriented versus Routine Stress Testing in High-Risk Patients Undergoing Percutaneous Coronary Intervention) study was a randomized trial comparing a follow-up strategy of routine functional testing at 1 year vs. standard care alone after high-risk PCI. Randomization was stratified according to diabetes status. The primary outcome was a composite of death from any cause, myocardial infarction, or hospitalization for unstable angina at 2 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1706 randomized patients, participants with diabetes (n = 660, 38.7%) had more frequent comorbidities and a higher prevalence of complex anatomical or procedural characteristics than those without diabetes (n = 1046, 61.3%). Patients with diabetes had a 52% greater risk of primary composite events [hazard ratio (HR) 1.52; 95% confidence interval (CI) 1.02-2.27; P = .039]. The 2-year incidences of the primary composite outcome were similar between strategies of routine functional testing or standard care alone in diabetic patients (7.1% vs. 7.5%; HR 0.94; 95% CI 0.53-1.66; P = .82) and non-diabetic patients (4.6% vs. 5.1%; HR 0.89; 95% CI 0.51-1.55; P = .68) (interaction term for diabetes: P = .91). The incidences of invasive coronary angiography and repeat revascularization after 1 year were higher in the routine functional-testing group than the standard-care group irrespective of diabetes status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Despite being at higher risk for adverse clinical events, patients with diabetes who had undergone high-risk PCI did not derive incremental benefit from routine surveillance stress testing compared with standard care alone during follow-up.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37933514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37933514</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad722>10.1093/eurheartj/ehad722</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37933514</guid>
<pubDate>Tue, 07 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Hoyun Kim</dc:creator>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Jinho Lee</dc:creator>
<dc:creator>Yeonwoo Choi</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Seonok Kim</dc:creator>
<dc:creator>Yong-Hoon Yoon</dc:creator>
<dc:creator>Seung-Ho Hur</dc:creator>
<dc:creator>Cheol Hyun Lee</dc:creator>
<dc:creator>Won-Jang Kim</dc:creator>
<dc:creator>Se Hun Kang</dc:creator>
<dc:creator>Chul Soo Park</dc:creator>
<dc:creator>Bong-Ki Lee</dc:creator>
<dc:creator>Jung-Won Suh</dc:creator>
<dc:creator>Jae Woong Choi</dc:creator>
<dc:creator>Kee-Sik Kim</dc:creator>
<dc:creator>Su Nam Lee</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:date>2023-11-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Routine stress testing in diabetic patients after percutaneous coronary intervention: the POST-PCI trial</dc:title>
<dc:identifier>pmid:37933514</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad722</dc:identifier>
</item>
<item>
<title>Patisiran is beneficial for the treatment of TTR cardiac amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37932423/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 6. doi: 10.1038/s41569-023-00955-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37932423/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37932423</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00955-2>10.1038/s41569-023-00955-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37932423</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Patisiran is beneficial for the treatment of TTR cardiac amyloidosis</dc:title>
<dc:identifier>pmid:37932423</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00955-2</dc:identifier>
</item>
<item>
<title>Drug-eluting resorbable scaffolds are superior to angioplasty for infrapopliteal artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37932422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 6. doi: 10.1038/s41569-023-00956-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37932422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37932422</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00956-1>10.1038/s41569-023-00956-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37932422</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Drug-eluting resorbable scaffolds are superior to angioplasty for infrapopliteal artery disease</dc:title>
<dc:identifier>pmid:37932422</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00956-1</dc:identifier>
</item>
<item>
<title>The Need for Randomized Trials to Define the Optimal Dose of Anticoagulants for Atrial Fibrillation in Chronic Kidney Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37931022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1455-1458. doi: 10.1161/CIRCULATIONAHA.123.066600. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37931022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37931022</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066600>10.1161/CIRCULATIONAHA.123.066600</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37931022</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sean D Pokorney</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Need for Randomized Trials to Define the Optimal Dose of Anticoagulants for Atrial Fibrillation in Chronic Kidney Disease</dc:title>
<dc:identifier>pmid:37931022</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066600</dc:identifier>
</item>
<item>
<title>Letter by Li et al Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37931021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1507-1508. doi: 10.1161/CIRCULATIONAHA.123.065349. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37931021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37931021</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065349>10.1161/CIRCULATIONAHA.123.065349</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37931021</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sha Li</dc:creator>
<dc:creator>Jie Qian</dc:creator>
<dc:creator>Jian-Jun Li</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Li et al Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</dc:title>
<dc:identifier>pmid:37931021</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065349</dc:identifier>
</item>
<item>
<title>Cardiovascular Diseases in Nigeria: Current Status, Threats, and Opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37931020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1441-1444. doi: 10.1161/CIRCULATIONAHA.123.063671. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37931020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37931020</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063671>10.1161/CIRCULATIONAHA.123.063671</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37931020</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Okechukwu Samuel Ogah</dc:creator>
<dc:creator>Olanike Allison Orimolade</dc:creator>
<dc:creator>Tomilola Olamide Jinadu</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Diseases in Nigeria: Current Status, Threats, and Opportunities</dc:title>
<dc:identifier>pmid:37931020</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063671</dc:identifier>
</item>
<item>
<title>Religiosity/spirituality as a medical prescription</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 1:ehad725. doi: 10.1093/eurheartj/ehad725. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37930863</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad725>10.1093/eurheartj/ehad725</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930863</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nandan S Anavekar</dc:creator>
<dc:creator>Ankur Kalra</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Religiosity/spirituality as a medical prescription</dc:title>
<dc:identifier>pmid:37930863</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad725</dc:identifier>
</item>
<item>
<title>Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 1:ehad667. doi: 10.1093/eurheartj/ehad667. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: For patients with symptomatic, severe tricuspid regurgitation (TR), early results of transcatheter tricuspid valve (TV) intervention studies have shown significant improvements in functional status and quality of life associated with right-heart reverse remodelling. Longer-term follow-up is needed to confirm sustained improvements in these outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The prospective, single-arm, multicentre TRISCEND study enrolled 176 patients to evaluate the safety and performance of transcatheter TV replacement in patients with ≥moderate, symptomatic TR despite medical therapy. Major adverse events, reduction in TR grade and haemodynamic outcomes by echocardiography, and clinical, functional, and quality-of-life parameters are reported to one year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Enrolled patients were 71.0% female, mean age 78.7 years, 88.0% ≥ severe TR, and 75.4% New York Heart Association classes III-IV. Tricuspid regurgitation was reduced to ≤mild in 97.6% (P &lt; .001), with increases in stroke volume (10.5 ± 16.8 mL, P &lt; .001) and cardiac output (0.6 ± 1.2 L/min, P &lt; .001). New York Heart Association class I or II was achieved in 93.3% (P &lt; .001), Kansas City Cardiomyopathy Questionnaire score increased by 25.7 points (P &lt; .001), and six-minute walk distance increased by 56.2 m (P &lt; .001). All-cause mortality was 9.1%, and 10.2% of patients were hospitalized for heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37930776</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad667>10.1093/eurheartj/ehad667</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930776</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Moody Makar</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Jyothy J Puthumana</dc:creator>
<dc:creator>Firas Zahr</dc:creator>
<dc:creator>Scott Chadderdon</dc:creator>
<dc:creator>Neil Fam</dc:creator>
<dc:creator>Geraldine Ong</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Vinod Thourani</dc:creator>
<dc:creator>Mani A Vannan</dc:creator>
<dc:creator>William W O'Neill</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>Didier Tchétché</dc:creator>
<dc:creator>Nicolas Dumonteil</dc:creator>
<dc:creator>Laurent Bonfils</dc:creator>
<dc:creator>Laurent Lepage</dc:creator>
<dc:creator>Robert Smith</dc:creator>
<dc:creator>Paul A Grayburn</dc:creator>
<dc:creator>Rahul P Sharma</dc:creator>
<dc:creator>Christiane Haeffele</dc:creator>
<dc:creator>Vasilis Babaliaros</dc:creator>
<dc:creator>Patrick T Gleason</dc:creator>
<dc:creator>Sammy Elmariah</dc:creator>
<dc:creator>Ignacio Inglessis-Azuaje</dc:creator>
<dc:creator>Jonathan Passeri</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:creator>Frank E Silvestry</dc:creator>
<dc:creator>Scott Lim</dc:creator>
<dc:creator>Dale Fowler</dc:creator>
<dc:creator>John G Webb</dc:creator>
<dc:creator>Robert Moss</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Stephane Lafitte</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Edwin Ho</dc:creator>
<dc:creator>Ythan Goldberg</dc:creator>
<dc:creator>Pinak Shah</dc:creator>
<dc:creator>Charles Nyman</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Elisabeth Bédard</dc:creator>
<dc:creator>Nicolas Brugger</dc:creator>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>TRISCEND study investigators</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study</dc:title>
<dc:identifier>pmid:37930776</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad667</dc:identifier>
</item>
<item>
<title>A change in the paradigm of antibiotic management in infective endocarditis: are we ready?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 31:ehad529. doi: 10.1093/eurheartj/ehad529. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37930713</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad529>10.1093/eurheartj/ehad529</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930713</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nuria Fernández-Hidalgo</dc:creator>
<dc:creator>Ignacio Ferreira-González</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A change in the paradigm of antibiotic management in infective endocarditis: are we ready?</dc:title>
<dc:identifier>pmid:37930713</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad529</dc:identifier>
</item>
<item>
<title>Aortic Dissection in Marfan Syndrome: Protect the Tube of Life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 18:S0735-1097(23)07568-X. doi: 10.1016/j.jacc.2023.08.054. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37930286</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.054>10.1016/j.jacc.2023.08.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930286</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Alan C Braverman</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aortic Dissection in Marfan Syndrome: Protect the Tube of Life</dc:title>
<dc:identifier>pmid:37930286</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.054</dc:identifier>
</item>
<item>
<title>Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In our contemporary cohort, type B dissections are more common than type A dissections and occur at traditional nonsurgical thresholds. The associations of type B dissection with ARR, independent mitral valve surgery, and type II dissection suggest a more severe phenotype in the setting of prolonged life expectancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 18:S0735-1097(23)07569-1. doi: 10.1016/j.jacc.2023.08.055. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: With preventive aortic grafting decreasing the incidence of type A dissections in Marfan syndrome (MFS), most dissections are now type B, for which risk factors remain largely uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We explored the determinants of type B dissection risk in a large, single-center MFS registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Demographic and anthropometric features, cardiovascular disease, and surgical history were compared in patients with MFS with and without type B dissection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 336 patients with MFS, 47 (14%) experienced a type B dissection (vs type A in 9%). Patients with type B dissection were more likely to have undergone elective aortic root replacement (ARR) (79 vs 46%; P &lt; 0.001). Of the patients, 55% had type B dissection a mean of 13.3 years after ARR, whereas 45% experienced type B dissection before or in the absence of ARR; 41 patients (87%) were aware of their MFS diagnosis before type B dissection. Among those with predissection imaging, the descending aorta was normal or minimally dilated (&lt;4.0 cm) in 88%. In multivariable analyses, patients with type B dissection were more likely to have undergone ARR and independent mitral valve surgery, to have had a type II dissection, and to have lived longer.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In our contemporary cohort, type B dissections are more common than type A dissections and occur at traditional nonsurgical thresholds. The associations of type B dissection with ARR, independent mitral valve surgery, and type II dissection suggest a more severe phenotype in the setting of prolonged life expectancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37930285</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.055>10.1016/j.jacc.2023.08.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930285</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nupoor Narula</dc:creator>
<dc:creator>Richard B Devereux</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:creator>Xiaoyue Ma</dc:creator>
<dc:creator>Jonathan W Weinsaft</dc:creator>
<dc:creator>Leonard Girardi</dc:creator>
<dc:creator>Grace P Malonga</dc:creator>
<dc:creator>Mary J Roman</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry</dc:title>
<dc:identifier>pmid:37930285</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.055</dc:identifier>
</item>
<item>
<title>Hot topics in interventional cardiology: left main disease, heavily calcified coronary stenoses, and physiology-guided percutaneous coronary interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 1;44(41):4295-4299. doi: 10.1093/eurheartj/ehad721.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37930000</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad721>10.1093/eurheartj/ehad721</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930000</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hot topics in interventional cardiology: left main disease, heavily calcified coronary stenoses, and physiology-guided percutaneous coronary interventions</dc:title>
<dc:identifier>pmid:37930000</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad721</dc:identifier>
</item>
<item>
<title>Associations Between End-Tidal Carbon Dioxide During Pediatric Cardiopulmonary Resuscitation, CPR Quality, and Survival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>Background: Supported by laboratory and clinical investigations of adult cardiopulmonary arrest, resuscitation guidelines recommend monitoring end-tidal carbon dioxide (ETCO2) as an indicator of CPR quality but note that "specific values to guide therapy have not been established in children." Methods: This prospective observational cohort study was an NHLBI-funded ancillary study of children in the ICU-RESUScitation trial (NCT02837497). Hospitalized children (≤18 years of age and ≥37 weeks...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.066659. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Supported by laboratory and clinical investigations of adult cardiopulmonary arrest, resuscitation guidelines recommend monitoring end-tidal carbon dioxide (ETCO2) as an indicator of CPR quality but note that "specific values to guide therapy have not been established in children." <b>Methods:</b> This prospective observational cohort study was an NHLBI-funded ancillary study of children in the <i>ICU-RESUS</i>citation trial (NCT02837497). Hospitalized children (≤18 years of age and ≥37 weeks post-gestational age) who received chest compressions of any duration for cardiopulmonary arrest, had an endotracheal or tracheostomy tube at the start of CPR, and had evaluable intra-arrest ETCO2 data were included. The primary exposure was event-level average ETCO2 during the first 10 minutes of CPR (dichotomized as ≥20 mmHg vs. &lt;20 mmHg based on adult literature). The primary outcome was survival to hospital discharge. Secondary outcomes were sustained return of spontaneous circulation (ROSC), survival to discharge with favorable neurologic outcome, and new morbidity among survivors. Poisson regression measured associations between ETCO2 and outcomes as well as the association between ETCO2 and other CPR characteristics: 1) invasively measured systolic and diastolic blood pressures and 2) CPR quality and chest compression mechanics metrics (i.e., time to CPR start; chest compression rate, depth, and fraction; ventilation rate). <b>Results:</b> Among 234 included patients, 133 (57%) had an event-level average ETCO2 ≥20 mmHg. After controlling for <i>a priori</i> covariates, average ETCO2 ≥20 mmHg was associated with higher incidence of survival to hospital discharge (86/133 (65%) versus 48/101 (48%); aRR 1.33, CI95 1.04 - 1.69, p=0.023) and ROSC (95/133 (71%) versus 59/101 (58%); aRR 1.22, CI95 1.00 - 1.49, p=0.046) compared with lower values. ETCO2 ≥20 mmHg was not associated with survival with favorable neurologic outcome or new morbidity among survivors. Average ETCO2 ≥20 mmHg was associated with higher systolic and diastolic blood pressures during CPR, lower CPR ventilation rates, and briefer pre-CPR arrest durations compared with lower values. Chest compression rate, depth, and fraction did not differ between ETCO2 groups. <b>Conclusions:</b> In this multicenter study of children with in-hospital cardiopulmonary arrest, ETCO2 ≥20 mmHg was associated with better outcomes and higher intra-arrest blood pressures, but not with chest compression quality metrics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37929615</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066659>10.1161/CIRCULATIONAHA.123.066659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929615</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ryan W Morgan</dc:creator>
<dc:creator>Ron W Reeder</dc:creator>
<dc:creator>Dieter Bender</dc:creator>
<dc:creator>Kellimarie K Cooper</dc:creator>
<dc:creator>Stuart H Friess</dc:creator>
<dc:creator>Kathryn Graham</dc:creator>
<dc:creator>Kathleen L Meert</dc:creator>
<dc:creator>Peter M Mourani</dc:creator>
<dc:creator>Robert Murray</dc:creator>
<dc:creator>Vinay M Nadkarni</dc:creator>
<dc:creator>C Nataraj</dc:creator>
<dc:creator>Chella A Palmer</dc:creator>
<dc:creator>Neeraj Srivastava</dc:creator>
<dc:creator>Bradley Tilford</dc:creator>
<dc:creator>Heather A Wolfe</dc:creator>
<dc:creator>Andrew R Yates</dc:creator>
<dc:creator>Robert A Berg</dc:creator>
<dc:creator>Robert M Sutton</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations Between End-Tidal Carbon Dioxide During Pediatric Cardiopulmonary Resuscitation, CPR Quality, and Survival</dc:title>
<dc:identifier>pmid:37929615</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066659</dc:identifier>
</item>
<item>
<title>Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>Background: Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.066213. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies, including bempedoic acid, an agent that reduces both LDLC and hsCRP. <b>Methods:</b> The multinational CLEAR-Outcomes trial (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen Outcomes Trial) randomly allocated 13970 statin-intolerant patients to 180 mg of oral bempedoic acid daily or matching placebo and followed them for a 4-component composite of incident myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and for all-cause mortality. Quartiles of increasing baseline hsCRP and LDLC were assessed as predictors of future adverse events after adjustment for traditional risk factors and randomized treatment assignment. <b>Results:</b> Compared with placebo, bempedoic acid reduced median hsCRP by 21.6% and mean LDLC levels by 21.1% at 6 months. Baseline hsCRP was significantly associated with the primary composite end point of major cardiovascular events (highest versus lowest hsCRP quartile; hazard ratio [HR], 1.43 [95% CI, 1.24-1.65]), cardiovascular mortality (HR, 2.00 [95% CI, 1.53-2.61]), and all-cause mortality (HR, 2.21 [95% CI, 1.79-2.73]). By contrast, the relationship of baseline LDLC quartile (highest versus lowest) to future events was smaller in magnitude for the primary composite cardiovascular end point (HR, 1.19 [95% CI, 1.04-1.37]) and neutral for cardiovascular mortality (HR, 0.90 [95% CI, 0.70-1.17]) and all-cause mortality (HR, 0.95 [95% CI, 0.78-1.16]). Risks were high for those with elevated hsCRP irrespective of LDLC level. Bempedoic acid demonstrated similar efficacy in reducing cardiovascular events across all levels of hsCRP and LDLC. <b>Conclusions:</b> Among contemporary statin-intolerant patients, inflammation assessed by hsCRP predicted risk for future cardiovascular events and death more strongly than hyperlipidemia assessed by LDLC. Compared with placebo, bempedoic acid had similar efficacy for reducing cardiovascular risk across hsCRP and LDLC strata.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37929602</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066213>10.1161/CIRCULATIONAHA.123.066213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929602</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Lei Lei</dc:creator>
<dc:creator>Michael J Louie</dc:creator>
<dc:creator>Tariq Haddad</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance</dc:title>
<dc:identifier>pmid:37929602</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066213</dc:identifier>
</item>
<item>
<title>A Diagnostic CopyCat: Culture-Negative Infective Endocarditis of a Bioprosthetic Valve Presenting as ANCA Vasculitis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067136. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37929592</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067136>10.1161/CIRCULATIONAHA.123.067136</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929592</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>David E Hamilton</dc:creator>
<dc:creator>Sandro K Cinti</dc:creator>
<dc:creator>Cathryn J Lapedis</dc:creator>
<dc:creator>Kim A Eagle</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Diagnostic CopyCat: Culture-Negative Infective Endocarditis of a Bioprosthetic Valve Presenting as ANCA Vasculitis</dc:title>
<dc:identifier>pmid:37929592</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067136</dc:identifier>
</item>
<item>
<title>Meta-analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231108031047&amp;v=2.17.9.post6+86293ac
      <description>Background: Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy (LVH) and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease, as penetrance (proportion of G+ who develop disease) is variable, age-dependent, and not reliably predicted. Methods: A systematic search of the literature was performed. We employed random...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.065987. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy (LVH) and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease, as penetrance (proportion of G+ who develop disease) is variable, age-dependent, and not reliably predicted. <b>Methods:</b> A systematic search of the literature was performed. We employed random effects generalized linear mixed model meta-analyses to contrast the cross-sectional prevalence and penetrance of sarcomere genes in two different contexts: clinically-based studies on patients and families with HCM versus population/community-based studies. Longitudinal family/clinical studies were additionally analyzed to investigate the rate of phenotypic conversion from subclinical to overt HCM during follow-up. <b>Results:</b> 455 full text manuscripts were assessed. In family/clinical studies, the prevalence of sarcomere variants in patients diagnosed with HCM was 34%. The penetrance across all genes in non-proband relatives carrying P/LP variants identified during cascade screening was 57% (95% confidence interval [CI] [52,63]) and the mean age of HCM diagnosis was 38 years (95% CI [36, 40]). Penetrance varied from ~32% for myosin light chain (<i>MYL3</i>) to ~55% for myosin binding protein C (<i>MYBPC3</i>), ~60% troponin T (<i>TNNT2</i>) and troponin I (<i>TNNI3</i>), and ~65% for myosin heavy chain (<i>MYH7</i>). Population-based genetic studies demonstrate that P/LP sarcomere variants are present in the background population, but at a low prevalence of &lt;1%. The penetrance of HCM in incidentally identified P/LP variant carriers was also substantially lower; approximatively 11%, ranging from 0% in Atherosclerosis Risk in Communities to 18% in UK Biobank. In longitudinal family studies, the pooled phenotypic conversion across all genes was 15% over an average of ~8 years of follow up, starting from a mean age of ~16 years. However, short-term gene-specific phenotypic conversion varied between ~12% for <i>MYBPC3</i> to ~23% for <i>MYH7</i>. <b>Conclusions:</b> The penetrance of P/LP variants is highly variable and influenced by currently undefined and context-dependent genetic and environmental factors. Additional longitudinal studies are needed to improve understanding of true lifetime penetrance in families and in the community, and to identify drivers of the transition from subclinical to overt HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231108031047&v=2.17.9.post6+86293ac">37929589</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065987>10.1161/CIRCULATIONAHA.123.065987</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929589</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Constantin-Cristian Topriceanu</dc:creator>
<dc:creator>Alexandre C Pereira</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Gabriella Captur</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Meta-analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37929589</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065987</dc:identifier>
</item>





























</channel>
</rss>